IP Library Granted Patent US 9,233,167
Granted Patent B2
US 9,233,167 · App. 14/581,721 · Granted Jan 12, 2016

Oligomer-opioid agonist conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,167
App. No.
14/581,721
Granted
Jan 12, 2016
Kind
B2
Abstract

The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.

Claims (15)

1. A compound according to the following formula:

wherein n is an integer from 1 to 30.

2. The compound of claim 1 , wherein n is 2 to 30.

3. The compound of claim 1 , wherein n is 1 to 10.

4. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient.

5. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form.

6. A method of treating pain in a subject comprising administering a compound of claim 1 to the subject.

7. A compound comprising a residue of oxymorphone covalently attached to a poly(ethylene oxide).

8. The compound of claim 7 , wherein the poly(ethylene oxide) is made of between 1 and 30 monomers.

9. The compound of claim 8 , wherein the poly(ethylene oxide) is made of between 1 and 10 monomers.

10. The compound of claim 7 , wherein the poly(ethylene oxide) includes an alkoxy or hydroxy end-capping moiety.

11. The compound of claim 7 , wherein a single poly(ethylene oxide) is attached to the residue of oxymorphone.

12. A composition comprising a compound of claim 7 , and optionally, a pharmaceutically acceptable excipient.

13. A composition of matter comprising a compound of claim 7 , wherein the compound is present in a dosage form.

14. A method of treating pain in a subject comprising administering a compound of claim 7 to the subject.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: INHERIS BIOPHARMA, INC.
To: NEKTAR THERAPEUTICS
Reel/Frame 062313/0501 →
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: INHERIS BIOPHARMA, INC.
Reel/Frame 052435/0062 →
CHANGE OF NAME Recorded Nov 15, 2019
From: INHERIS PHARMACEUTICALS, INC.
To: INHERIS BIOPHARMA, INC.
Reel/Frame 051038/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: NEKTAR THERAPEUTICS
To: INHERIS PHARMACEUTICALS, INC.
Reel/Frame 050846/0461 →
SECURITY INTEREST Recorded Oct 28, 2019
From: INHERIS PHARMACEUTICALS, INC.
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 050846/0940 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 35087, FRAME 0975 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036856/0567 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2015
From: RIGGS-SAUTHIER, JENNIFER; DENG, BO-LIANG; RILEY, TIMOTHY A.
To: NEKTAR THERAPEUTICS
Reel/Frame 036365/0129 →
SECURITY INTEREST Recorded Mar 4, 2015
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 035087/0975 →